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Electroacupuncture (EA) pretreatment is a recent observation which has been shown to induce ischemic tolerance mimicking
the ischemic pretreatment, suggesting that EA pretreatment may be a promising preventive strategy for the patients with high
risk of acute ischemia/reperfusion injury. It was ﬁrst described in the brain, then in the heart where EA stimulation at acupoint
prior to ischemia led to neuroprotection and myocardial protection and induced rapid and delayed ischemic tolerance. Then
the optimal parameters and acupoint speciﬁcity of EA pretreatment to induce protective eﬀect were proved. Many studies have
shown that protective mechanisms of EA pretreatment may involve a series of regulatory molecular pathways including activity
enhancementofantioxidant,regulationoftheendocannabinoidsystem,involvementofbeta-adrenergicreceptor,andpostreceptor
signaling pathway, inhibition of apoptosis. Recently, the neuroprotective and cardioprotective eﬀect of EA pretreatment had been
demonstrated in patients undergoing craniocerebral tumor resection or heart valve replacement surgery. Thus, the purpose of
this paper is to collect the evidence for the neuroprotective eﬀect of EA pretreatment, to summarize the proposed protective
mechanisms of EA pretreatment, and to discuss the possibility of EA pretreatment as a new preventive strategy for patients with
high risk of ischemia in clinic.
1.Introduction
Stroke is the second most common cause of death and re-
sults in a large number of people with disability worldwide.
Strokes are either ischemic or hemorrhagic, but more than
80% of stroke cases are caused by cerebral ischemia [1].
Although many neuroprotective agents have been proved to
reduce infarction volume and improve neurological recovery
in basic research with animal models of stroke, few of
them show eﬀects in clinical trials [2, 3]. Moreover, most
of the currently used pharmacotherapies are focused on
treatment after ischemia, such as tissue plasminogen activa-
tor (t-PA), to remove the thrombus and reestablish blood
perfusion in ischemic region. Although t-PA facilitates the
revascularization when given at the early stage (up to 3h)
after ischemia, the safety and eﬃcacy of t-PA at late stage
(beyond3.5h)remaincontroversial[4].Theneuroprotective
agent Edaravone, a free radical scavenger, has been approved
internationally to treat cerebral ischemia recently. However,
itcanneitherstoptheprocessofinfarctionoredemaafterthe
stroke, nor improve the neurological outcomes of survivals
[5]. Although there are some eﬀective drugs like antiplatelets
and anticoagulants to prevent stroke, the possibility of caus-
ing hemorrhage has limited the application of these drugs.
Therefore, it is a huge and urgent medical need to develop
novel and rational strategies aimed at preventing ischemia/
reperfusion (I/R) injury as well as reducing impairments
caused by I/R.
The phenomenon of pretreatment induced ischemic tol-
erance provides a new idea for the prevention of I/R injury.
The pretreatment eﬀect is that a brief exposure to sublethal
or noninjurious stimuli can increase resistance to the sub-
sequent prolonged and lethal damage [6]. There are various
kinds of pretreatment measures, such as ischemia (regional
or remote), hypoxia, endotoxin, cytokines, and anesthetics.2 Evidence-Based Complementary and Alternative Medicine
Accumulating preclinical evidences has demonstrated that
these pretreatment methods, especially ischemia pretreat-
ment, could induce neuroprotection and myocardial protec-
tion against I/R injury [7, 8]. But from the clinical point of
view, all the mentioned pretreatment ways have limitations
and adverse eﬀects to be applied in patients, especially the
patients with severe illness.
EA is a novel therapy based on traditional acupuncture
combined with modern electrotherapy. Due to the beneﬁcial
eﬀects of acupuncture to diﬀerent brain and heart diseases,
EA has been used in treatment as an improvement on tra-
ditional acupuncture. Evidence shows that EA not only re-
duces the myocardial injury but also signiﬁcantly promotes
recovery of neurological function and, thus, improve their
quality of life [9].
In recent years, numerous studies have shown that EA
also have pretreatment eﬀect, inducing ischemic tolerance as
well [10, 11]. Since EA is economical, easily performed, and
has few negative side eﬀects, it is clinically applicable for pre-
vention, and not just treatment of ischemic cardiac/cerebral
disease.Inthispaper,wediscussevidenceofEApretreatment
induced neuroprotection both from animal experiments and
clinical trials, parameters of EA pretreatment, and some
mechanisms involved in this eﬀect. Because heart shares
lots of characters with brain, especially in I/R injury, and
r e s e a r c h e r sh a v ed o n el o t so fw o r ko fE Ap r e t r e a t m e n to n
heart, the myocardial protective eﬀects of EA pretreatment
are included.
2. EAOriginatesfrom Acupuncture
Acupuncture, an alternative medicine derived from Chinese
traditional medicine, is a procedure in which ﬁne nee-
dle is inserted into patients at discrete acupoint and ma-
nipulated. Although it is ﬁrst developed in China, it has
spread worldwide and used to treat various diseases [12].
Since stimulation of acupuncture is supposed to be tightly
associated with nervous system, acupuncture is expected to
improve the neurological function after stroke. Although
two systematic reviews indicated that the evidence is not
enough to support the positive eﬀect of acupuncture on
functional recovery after stroke [13, 14], a lot of clinical trials
haveveriﬁedthatacupuncturestimulationimprovedbalance
function [15] and spastic states [16], in stroke patients,
reduced muscle spasticity and improved motor function for
chronic stroke survivors with moderate or severe muscle
spasticity [17]. Acupuncture also improved function of the
aﬀected upper limb in chronic hemiparetic stroke patients
by increasing activity in the ipsilesional motor cortex [18].
In addition, 46% of stroke survivors in the United States
engaged in some form of complementary and alternative
medicine (CAM) therapy, in which acupuncture was the
most frequently used CAM therapy in stroke survivors [19].
However, the beneﬁcial eﬀects of acupuncture in stroke
patients required more high-quality evidence [20].
Integrated with electrotherapy, EA is conducted by in-
serting acupuncture needles into acupoints and then chang-
ing electric stimulation parameters, including the stimu-
lation frequency, current intensity, pulse width, and pulse
interval [21]. Except for a small current passing through a
pair of needles, EA is similar to the regular acupuncture.
Thus, EA not only inherits the beneﬁts of traditional acu-
puncture, but also integrates with the physiological eﬀects of
electric stimulation [21].
Compared with regular acupuncture, there are two ad-
vantages for EA. On the one hand, the acupoint of EA is
not as precise as regular acupuncture, since current delivered
by needles stimulates a larger area than that of needle itself.
On the other hand, there is an alternative technique for EA,
which is called transcutaneous electrical nerve stimulation
(TENS). TENS uses electrodes which are taped to the surface
of the skin other than needles being inserted, so it can be
applied in condition that patients deny insertion of needle
or cannot be needled. Based on these two advantages, a
growing number of basic researches and clinical trials are
preceded in investigating the neuroprotective eﬀect of EA
and mechanism of this eﬀect. A large number of animal
studies have shown that EA could reduce neural apoptosis,
promote cell proliferation, increase cerebral blood ﬂow
(CBF), and improve neurological function after stroke [22–
25]. These results provide some evidence for further trans-
lational studies. So far, some clinical trials have focused
on the eﬀects of EA in stroke patients, but the results
are ambiguous. Although many investigations with small
e n r o l l m e n t ss u p p o r tt h a tE At r e a t m e n th a sp o s i t i v ee ﬀects
on the motor function and quality of life [9, 26], two
randomized controlled trials including more patients ﬁnd
that there is no signiﬁcant diﬀerence between EA group and
control group in improvement of functional outcome and
life satisfaction [27, 28]. In respect to this contradiction, the
new method of EA treatment is required for further clinical
application.
3.“PreventiveAcupuncture”and
EAPretreatment
As an indispensable part of traditional Chinese medicine,
acupuncture has played an important role in prevention and
treatment of diseases throughout history. “Treating before
sick” is the plain idea of preventive medicine in traditional
Chinese medicine. “Preventive acupuncture” is an approach
using acupuncture to “treat before sick.” Namely, applying
acupuncture in healthy or mildly sick patients to stimulate
the meridians of the body and enhance the body’s resistance
to disease, in order to prevent disease or to reduce the
extent of damage following disease [29]. In general, most
of preclinical studies and clinical trials on EA focused on
its therapeutic role after stroke. However, prevention is def-
initely superior to treatment. Since EA is economical, easily
operated, and has fewer negative side eﬀects than the other
prevention methods (e.g., pharmacological, ischemic, etc.),
it should be more valuable and advantageous in preventing
ischemiccerebralvasculardisease,especiallyonpatientswith
high risk of ischemic injury.
In 2003, Xiong and colleagues, the results of whose
research were shown in Figure 1, ﬁrst deﬁned the con-
cept of EA pretreatment. They reported that repeated EAEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Identiﬁcation (deﬁnition) of EA pretreatment. This graph shows the infarct volume of brain 24h after MCAO for 120min in
rats. (a) Representative pictures of coronal sections of rat brain after infarction stained with 2,3,5-triphenyltetrazoliumchloride. (b) The
bar graph showing the statistical analysis for infarct volumes in 3 groups. CON: control group; ISO: isoﬂurane pretreatment group; EA:
electroacupuncture pretreatment group. (n = 10, ∗P<0.05, ∗∗P<0.01). This ﬁgure was adapted from [10].
stimulation at the Baihui acupoint (GV20) before cere-
bral ischemia in rats could signiﬁcantly reduce infarct
volume caused by transient middle cerebral artery occlu-
sion (MCAO) (38.3 ± 25.4mm 3 in the EA group versus
220.5±66.0mm 3 in the control group and 168.6±57.6mm 3
in the anesthetized group) and improve later neurological
outcomes [10]. The results showed that EA stimulation
before ischemia could produce an eﬀect similar to ischemia
pretreatment and induce ischemic tolerance. Later, this
group showed that pretreatment with a single EA session
could also induce tolerance to focal cerebral ischemia in
rats [11]. At the same time, another group [30] found that
EA pretreatment at Hegu (LI4), a well-known acupoint
commonly used in Oriental medicine for the treatment of
neuronal injury resulting from hypoxia-ischemia, could in-
duce neuroprotective eﬀect in neonatal hypoxic-ischemic rat
brains.
Just like ischemia pretreatment, EA pretreatment has
potential protective eﬀects on mammalian brain. Further-
more, both ischemia pretreatment and EA pretreatment can
produce the acute and delayed neuroprotection. A single EA
stimulation at Baihui acupoint for 30 minutes could induce
biphasic tolerance against focal cerebral ischemia: the acute
phase occurred 2 hours after EA pretreatment while the
delayed ischemic tolerance was observed 24 hours after the
stimulus [11].
The neuroprotective eﬀect of EA pretreatment not only
exists in ischemic cerebral injury. Recently, researchers found
that EA pretreatment could reduce pathological injury in
hippocampal neurons, decrease the expression of activated
caspase-3, reduce the number of apoptotic neurons in the
CA1 area, and improve learning and memory in rats exposed
to high-sustained positive hypergravity (+Gz) [31]. The
results showed that EA pretreatment could ameliorate +Gz-
induced impairment of learning and memory by inhibiting
neuronal apoptosis.
In addition, EA pretreatment was also observed in heart.
Researchers applied EA to bilateral Neiguan (PC6) before or
during myocardial I/R induced by ligating and reperfusing
the left anterior descending coronary artery. The results
showed that there were signiﬁcant reductions in cardiac en-
zymes, the duration of arrhythmia, and mortality rate in rats
that were either preconditioned or treated with EA on PC6,
compared with those that did not underwent EA [32].
4.OptimalParametersofEAPretreatment
Although EA pretreatment could induce neuroprotective
eﬀect similar to ischemic pretreatment, there are some char-
acters about EA pretreatment diﬀerent from other pretreat-
ment ways, especially the electrical stimulation parameters
and the acupoint speciﬁcity. The parameters and acupoint
deﬁning the protective eﬀectofEApretreatmentaresumma-
rized in Table 1.
The electric stimulation parameters (frequency, pulse
width, current intensity, and duration) and their quantiﬁ-
cation are important parts of the research on EA. Studies
have shown that electric stimulation of diﬀerent parameters
may have diﬀerent eﬀects on some body functions. Nested
design [45] was adopted to identify the inﬂuence of diﬀerent
parameters and their combination on EA pretreatment in-
duced cerebral ischemic tolerance in rats. This study at last
conﬁrmed the appropriate electrical stimulation parameters
of EA pretreatmentto induce cerebral ischemic tolerance
in rats: density-sparse wave of 2/15Hz, current intensity
of 1mA, and 30min/d for 5 consecutive days. The results
showed varying frequency and waveform of the stimulus
could produce diﬀerent protective eﬀects, but there were no
signiﬁcant diﬀerences in infarct volume between rats that
received stimulation from 1mA to 3mA current intensity,
indicating that frequency and waveform were probably more
important parameters than current. Density-sparse wave4 Evidence-Based Complementary and Alternative Medicine
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had the most obvious neuroprotective eﬀect, followed by
intermittent wave, and the continuous wave’s neuroprotec-
tive eﬀect was relatively poor. The reason for this is prob-
ably that continuous wave tended to induce tolerance of
the electric stimulus, whereas density-sparse wave could
stimulate the release of diﬀerent types of neurochemicals by
transformation between low, medium, and high frequency
stimuli. Therefore, the density-sparse wave EA stimulation
could generate neuroprotective eﬀect at diﬀerent targets via
the activation of diﬀerent signaling pathways.
5. AcupointSpeciﬁcityof EAPretreatment
Based on meridian theory, an acupoint is relatively speciﬁc
to certain functions or certain organs, and diﬀerent eﬀects
occur when diﬀerent acupoints are stimulated. The neuronal
speciﬁcityofacupointhasbeentestedbyfunctionalmagnetic
resonance imaging (fMRI), providing neurobiological evi-
dence for the existence of acupoint speciﬁcity [46, 47]. Lu et
al. found that EA pretreatment of the Baihui acupoint could
induce more robust neuroprotection against cerebral I/R
injury than stimulation 1cm lateral to the Baihui acupoint
or nonmeridian points of the distal limbs [2]. The Baihui
acupoint was chosen because the theory of meridians in
traditional Chinese medicine indicates that the Du meridian
is closely related to the brain and spinal cord and Baihui is
one of the acupoints of the Du meridian. At the same time,
according to modern medicine, Baihui acupoint (GV20) is
in the projection area of the motor and sensory cortex,
as well as in the projection area of the anterior cerebral
artery. Therefore, Baihui is probably an important acupoint
in preventing and treating cerebral diseases. Similarly, EA
pretreatment at Weizhong acupoint (BL40) was more ben-
eﬁcial for spinal cord I/R injury in rabbits than pretreatment
at the Tsusanli acupoint (ST36) [48]. Hegu (LI4) was chosen
for the treatment of neuronal injury resulting from hypoxia-
ischemia [30], and Neiguan (PC6) was preferred in EA
pretreatment-inducedcardioprotection forits eﬀectonheart
disease [32].
6. Proposed Protective Mechanisms of
EAPretreatment
EA is pleiotropic and EA pretreatment could have multiple
complicatedinﬂuencesonthephysiologyofbrainandonthe
pathophysiology of cerebral ischemia. Although protective
mechanisms of EA pretreatment are largely unknown, a
series of studies have shown that EA pretreatment primarily
regulates oxidative stress [49], maintains the integrity of
blood-brain barrier (BBB) [40], and inhibits apoptosis [30,
33] via diﬀerent receptors, for example, adenosine receptor
type 1 (A1R) [11], opiod receptors [37], cannabinoid recep-
tors (CB1, CB2) [41–44], N-methyl-d-aspartate receptors
(NMDARs) [39], and downstream intracellular signaling
events including KATP channels [30], extracellular regulated
kinase(ERK)[42],epsilonproteinkinaseC(εPKC)[44],and
phosphatidylinositol 3-kinase (PI3K) pathway [50], while
the researches of myocardial protective mechanisms induced
by EA pretreatment mainly focus on β-adrenoreceptor (β-
AR) and postreceptor signaling pathway [34–36, 38, 51].
Signaling pathways involved in the neuroprotection of EA
pretreatment were summarized in Figure 2.
6.1.EAPretreatmentRegulatesOxidativeStress,Maintainsthe
Integrity of BBB, and Inhibits Apoptosis. Abrupt reperfusion
after ischemia results in overproduction of reactive oxygen
species,whichleadstothebraininjury[52].EApretreatment
enhances the activity of mitochondrial respiratory enzymes,
attenuates lipid peroxidationand and reduces the production
of reactive oxygen species (ROS), consequently improving
the function of the respiratory chain and antioxidant capaci-
tyintheischemicpenumbra[49,53].Inaddition,itincreases
the levels of antiapoptotic genes like Bcl-2 while decreasing
the levels of proapoptotic genes such as c-Jun and c-Fos,
inhibiting subsequent apoptotic cascades [30, 33]. Jiang et al.
also found that the antagonizing eﬀect of EA pretreatment
on cerebral hypoxic/ischemic injury may be related to its
activationofKATP,inhibitingtheneuronalapoptosisinduced
by the immediate genes c-Fos and c-Jun at early injury stages
[33].
Moreover, BBB integration and stress reactions are
involved in the neuroprotection after EA pretreatment. BBB
integration is disrupted by cerebral ischemia, resulting in the
brain edema. Matrix metalloproteinases (MMPs) are neutral
proteases that disrupt the BBB and are associated with
subcortical ischemic vascular disease [54]. The expression
and activity of matrix metalloproteinases-9 (MMP-9), one
of MMPs, are decreased after EA pretreatment, and subse-
quently the brain edema and BBB damage are signiﬁcantly
alleviated [40]. This phenomenon has also been observed
in another experiment, which indicates that ERK pathway is
involved in this process [55].
6.2. Endocannabinoid System Contributes to the Neuroprotec-
tive Eﬀects of EA Pretreatment. Recent investigations have
shownthattheendocannabinoidsystemmaybeanewmech-
anismofEApretreatment-inducedneuroprotection. EApre-
treatment increases the release of 2-arachidonylglycerol (2-
AG)andN-arach-idonoylethanolamine-anandamide(AEA),
2 endocannabinoids and upregulates the expression of can-
nabinoid CB1 receptor in brain. Selective CB1 antagonist
AM251 or CB1 short interfering RNA (siRNA) blocked the
neuroprotective eﬀects of EA pretreatment. Meanwhile, pre-
treatment with 2-AG and AEA also reduced infarct size and
improved neurological outcomes [41]. Moreover, further
study [43] showed that both acute and delayed ischemic
tolerance were associated with endocannabinoid system: the
acute phase which occurred in 2 hours after the EA pre-
treatment was mediated by CB1, whereas the delayed phase
occurred in 24 hours after the EA pretreatment via CB2 [43].
These ﬁndings indicated that the endocannabinoid system
plays an important role in the neuroprotective eﬀect of EA
pretreatment.
Activation of the CB1 receptor triggers signaling trans-
duction events that can inﬂuence ischemic compensatory
responses. Cellular responses that elicit neuroprotection may6 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Involvement of cell signaling pathways in neuroprotection of EA pretreatment. This diagram shows the cell signaling pathways
involved in the cerebral ischemic tolerance induced by EA pretreatment. PKA: protein kinase A; ERK: extracellular-regulated kinase;
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involve CB1 receptors and their link to a variety of signal-
ing elements, including the Gi/Go family of G-proteins,
mitogen-activated protein kinase (MAPK), kinase (MEK1/
2), and its substrate, ERK1/2. Further studies have demon-
stratedthattheneuroprotectionofEApretreatmentcouldbe
abolished by U0126 (a speciﬁc inhibitor of the MEK1/2) or
TAT-εV1-2(anεPKC-selectivepeptideinhibitor).Theblock-
ade of CB1 receptor by a CB1 receptor antagonist AM251
reversed the activation of ERK1/2 and εP K Cr e s u l t e df r o m
EA pretreatment. These ﬁndings suggest that the ERK1/2
and εPKC pathway might be involved in EA pretreatment-
induced cerebral ischemic tolerance via the cannabinoid
CB1 receptor [42, 44]. Figure 3 shows the endocannabinoid
systemandthepostreceptorsignalingpathwayinvolvedinits
neuroprotective eﬀect.
6.3. EA Pretreatment Attenuates Glutamate Excitotoxicity via
NMDAR. Cerebral ischemia induces excessive glutamate re-
lease and excitotoxicity [57]. Transient increase of cerebral
blood ﬂow (CBF) during reperfusion (hyperemia) wouldEvidence-Based Complementary and Alternative Medicine 7
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aggravate the brain injury induced by excitotoxicity. Pre-
, intra-, or posttreatment of EA could rescue hippocampal
neurons from ischemic insults via decreasing the production
of glutamate and reducing hyperemia [39, 58]. Previ-
ous studies indicated that NMDARs are responsible for
glutamate-induced excitotoxicity in the postischemic brain
[57, 59]. EA pretreatment suppresses the expression of NR1,
a subunit of the NMDARs, which may contribute to its ef-
fect in reducing apoptosis and protecting cerebral neurons
[39]. Further study suggested that reduced NR1 expression
could be reverted by speciﬁc inhibitors of the PI3K pathway,
but inhibition of the ERK pathway did not show the same
eﬀects [50]. Therefore, EA pretreatment attenuates gluta-
mate excitotoxicity by modulating the PI3K pathway.
6.4. β-Adrenoreceptor and Postreceptor Signaling Pathway Are
Involved in Cardioprotection EA Pretreatment. The mecha-
nism of EA pretreatment in the heart is not entirely identical
to brain [34–36, 38, 51]. Studies have shown that EA pre-
treatment can signiﬁcantly attenuate the incidence of ar-
rhythmia and enhance myocardial cAMP and Gs alpha
protein after I/R injury [35, 36]. This attenuating eﬀect was
signiﬁcantly inhibited by the intraperitoneal pretreatment
with propranolol, a speciﬁc β-AR antagonist [34]. These
results indicated that EA pretreatment was antiarrhythmic
after myocardial I/R, and is mediated by the postreceptor
signaling pathway of the β-AR. Later, the same group
found that adenylatecyclase, protein kinase A, and L-type
Ca2+ channel, the β-AR signaling components modulating
intracellular Ca2+([Ca2+])i, were involved in mediating the
neuroprotection of EA pretreatment in the isolated rat hearts
subjected to simulated global ischemia and reperfusion [38].
Pretreatment with EA can eﬀectively resist myocardial I/R-
induced arrhythmia and intracellular calcium oscillation in
the rats [51].
7. ClinicalApplicationof EA Pretreatment
Although EA pretreatment has been shown to reduce ce-
rebral ischemic injury in numerous preclinical studies, it
is unclear whether EA pretreatment could also be applied
to clinical practice. The latest clinical trials provide some
evidence for the eﬀectiveness of EA pretreatment in patients.
To study neuroprotection after EA pretreatment, Lu et
al. enrolled 32 patients requiring selective craniocerebral
tumor resection, and randomly assigned them to EA or con-
trol groups. At 2 hours before surgery, patients in the EA
gr oupr ec ei v edEAstimulationatF engfu(Du16)andF engchi
acupoint (GB20) for 30 minutes. Patients in the control
group received no pretreatment. The results showed that the
serum levels of S100 calcium-binding protein β (S-100β)
and neuron-speciﬁc enolase (NSE) in the EA group were
signiﬁcantly lower than in the control group at the end of the
surgery and 24 hours after surgery [56]. This study indicated8 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of EA pretreatment in clinical trials. This diagram shows the results of 2 clinical trials concerning the neuroprotection and
myocardial protection of EA pretreatment. (a, b) Neuroprotective eﬀect of EA pretreatment in patients undergoing craniocerebral tumor
resection ((a) changes of S100β at diﬀerent time points; (b) changes of NSE at diﬀerent time points). (c, d) Myocardial protection of EA
pretreatment in patients undergoing heart valve replacement surgery ((c) serum cTnI levels during 72 hours after the removal of aorta cross-
clamping; (d) inotrope scores over the ﬁrst 48 hours after arrival in the ICU). EA: electroacupuncture; S100β: S100 calcium-binding protein
β; NSE: neuronspeciﬁc enolase; cTnI: cardiac troponin I; ICU: intensive care unit. These ﬁgures ware adapted from [44, 56].
that EA pretreatment might have potential protective eﬀects
on surgical brain damage.
In the same year, Yang and colleagues also designed a
randomized controlled trial enrolling 60 patients to inves-
tigate the cardioprotective eﬀect of EA pretreatment in pa-
tients undergoing heart valve replacement surgery [60]. EA
or sham stimuli were applied at bilateral Neiguan (PC6),
Lieque (LU7), and Yunmen (LU2) for 30 minutes each day
f o rﬁ v ec o n s e c u t i v ed a y sb e f o r es u r g e r y .T h el e v e lo fs e r u m
cardiac troponin I was signiﬁcantly decreased in the EA
groupat6,12,and24hoursafteraorticcross-clampremoval.
Meanwhile, EA pretreatment also reduced the inotrope use
at 12, 24, and 48 hours after the intensive care unit arrival
and shortened intensive care unit stay time [60]. The re-
sults demonstrated that EA pretreatment might alleviate
cardiac I/R injury in adult patients undergoing heart valve
replacements.
Results of the two trials were partly showed in Figure 4.
These two clinical trials have indicated that EA pretreatment
may have beneﬁcial eﬀects on patients undergoing surgery.
But, this evidence is limited since the number of enrolled
patients is small and both of these trials were conducted in
a single center. Thus, multiple center randomized controlled
trials are needed to provide further evidence on EA pretreat-
ment. Some other undergoing clinical trials concerning EA
pretreatment are summarized in Table 2.Evidence-Based Complementary and Alternative Medicine 9
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8. ConclusionandProspectsofEAPretreatment
Available data indicates that EA pretreatment can reduce
ischemiccerebralinjuryandimproveneurologicaloutcomes.
Like other pretreatment methods, EA pretreatment can in-
duce biphasic (acute and delayed) tolerance against cerebral
ischemia.However,unlikeotherpretreatmentmethods,neu-
roprotection induced by EA pretreatment is parameter-de-
pendent and acupoint-speciﬁc. Multilevel, multipathway,
and multitarget mechanisms have been identiﬁed in the
neuroprotective eﬀect of EA pretreatment.
However, all current studies just provide limited infor-
mation about mechanisms of EA pretreatment. Just like
other pretreatment methods, biochemical, morphological,
and behavioral changes induced by I/R injury after EA
pretreatment are intensively observed, and EA pretreatment
has been proved as the reason for the change. But, little work
focusesonthereasonwhyEAtreatmentbeforeI/Rinjurycan
inducechangeafterI/Rinjury.Forexample,EApretreatment
has been implicated to induce the overproduction of 2-AG
and AEA, thereby activating endocannabinoid system and
reducingbraindamageandfunctionaldeﬁcitafterI/Rinjury.
But, it is still unclear why EA treatment before ischemia can
inducethechangeofendocannabinoidsystemafterischemia.
W h a to c c u r sd u r i n gt h ep r o c e s so fE Ap r e t r e a t m e n tm u s tb e
explored.
In addition, although compared with other pretreatment
methods, EA pretreatment is economical, safe, and easily
operated, is more likely to be accepted by patients, and has
strong clinical applicability, there is still a gap between
potential beneﬁts of EA against ischemia and clinical appli-
cation of EA in neuroprotection. The beneﬁts of EA pre-
treatment are tightly associated with determination of EA
pretreatment parameters, such as frequency and duration
of pretreatment and speciﬁc acupoint. In most of current
studies, EA pretreatment parameters are selected according
to the neuroprotective eﬀects after I/R injury. But, this
method is not ﬁt for the clinical application. Therefore, it
is necessary to develop preischemic markers indicating the
eﬀectiveness of EA pretreatment. Once we ﬁnd a series of
biomarkers for EA pretreatment, it is possible that we
would apply individual EA pretreatment due to diﬀerent
genders, age groups, and pathological status such as diabetes.
Furthermore, on the basis of basic research and clinical
test, there is still not enough data for supporting the neu-
roprotective eﬀect of EA pretreatment. Thus, multicenter
randomized control trials should be carried out and may
provide evidence for determining the neuroprotective eﬀect
of EA pretreatment and further clinical practice. Although
muchworkremains,ifwesuccessfullyﬁndsatisfyinganswers
to the above problems, we may turn the wishes of patients
suﬀering from cerebral ischemia to live a better life into
reality through EA pretreatment.
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